you've Done the hard bit. you've got regulatory approval. you've got two pilot sites ongoing. you've got distributor interest, but you've got limited runway. your sales aren't coming in like you want, and you can only choose one focus in the next 90 days. What do you prioritize? In the next seven minutes, I'm going to show you how to prioritize when everything feels urgent and why does only one move that you should take that will turn early traction into real commercial proof so that you can scale internationally without guessing. Welcome to Clinician to CEO, the podcast helping clinicians simplify your go-to-market strategy so that you can stop guessing and turn your working prototypes into international MedTech businesses. I'm your host, Hakeem Aade. Let's get started. Now in the last episode, I put this scenario to Mark Chuda. You're advising a clinical founder. They have regulatory approval. They have two pilot sites with good feedback. They have one distributor who's keen but unproven, and you have a limited cash runway. And 90 days before board pressure starts to kick in. The question, you can only choose one primary focus for the next 90 days. What is the. Primary focus and why I, what do you prioritize and why? A push hard on signing and onboarding the distributor to accelerate. Reach B. Double down on converting one pilot site into a fully scaled case. Study with hard data. C hire a commercial lead to build a structured pipeline. And messaging and d finally define the commercial narrative and economic case before pushing further. so Mark's answer was very simple and very quick. Actually, he said, B, convert one pilot into a fully scaled data backed case study. IE he said that you need to build proof because that will prove measurable economic value. It will ensure that you understand a clear procurement pathway, which will then help you move your product through much more quickly. It will also turn interest into evidence. 'cause at the moment what you've got is interest and you need evidence. And then the evidence can be turned into leverage with in other accounts and other countries. And I agree with him. So let me tell you why and let's break it down. The first things first, I want to clarify 'cause we talked about regulatory approval. And regulator approval is not traction, it's permission, it's the entry ticket. So it proves that your device is safe, that it's compliant, and that it's technically validated. But what it does not prove is that anyone's gonna buy it. Hospitals don't buy approvals, they buy outcomes. And if you confuse those two things, you're already gonna be on very, very thin ice. So now let's move on to the fact that you've got two pilot sites with good feedback. 'cause that matters. But good feedback isn't automatically commercial readiness. And the real question is this, have you extracted anything structured from those pilots, not just them saying they like it. So let me ask you something directly. Do you have measurable. Provable economic value that you've been able to prove from that pilot? Do you have proof of workflow integration? Do you know the procurement pathway? Do you know who actually signed off the pilot internally? Do you have repeat usage data? Because if you don't, then all you have is interest, and interest is fragile. Interest disappears when budget pressure hits. Interest disappears when a competitor walks in. Interest disappears. When the board asks you where the revenue, but what doesn't disappear is proof. That doesn't disappear. Proof strengthens your pricing conversations, proof shortens your sales cycle, and proof gives you confidence. And that's why we double down on this as a priority. And if you chose a for your priority, a onboard the new distributor, then the proof that you'll get from a case study is even more critical. And I'm not surprised if you chose Option A actually, because Keen Distributors lead. And always lead to excited founders because they're really keen. They love the product. They've got good reach, they've got great reach. In fact, now that's all good. And let's be fair, distributors can absolutely create demand in their market and make or break your product. And those markets, especially internationally, because they know the hospitals, they know the procurement route, they know the influencers. But what they can't do is invent a commercial case for you if you activate a distributor. Without a clear economic story, without defined positioning, without identifying the target segment and without structured onboarding, what you're actually asking them to do is figure out for themselves and good distributors. Don't want to do that, and they won't do that. What they want is clarity. They want confidence. They want something they can take into a hospital and say, here's why it works. Here's the data and here is the impact. If you give them that, then they can amplify demand in their market. If you don't, you're gonna find it really difficult. And sooner or later the distributor. It is gonna find it very difficult to sell and they'll start to switch off and six months later, it's not then that they've underperformed, it's that you weren't commercially ready for giving them that product and scaling in that market. Now you may well be thinking, okay, I understand that. I understand why you're not gonna go to the distributor. At first, but you're thinking why an option C though? Hire a commercial lead. And it's a fair question because if that commercial lead is going to help structure the pilot properly, extract economic value, build a procurement map, sharpen the positioning, then yes, that could make sense. But the fact that you've already got two pilots running would indicate that you've clearly got enough internal resource to execute them. So the question isn't, do we need more people? The question is, have we extracted the value from what we're already doing? Hiring someone before you've maximized the learning from your existing pilots can just add cost, not clarity. And with limited runway cost matters. You don't hire because you feel pressure. You need clarity before capacity always. So that's option C. Now, let's talk about option D. Refine the commercial narrative and economic case before pushing further on the surface. That sounds mature. It sounds like you're tightening the message, you're sharpening the pitch deck, you're reworking the positioning. But here's the problem. Narrative without evidence is just an opinion dressed up in very nice clothes. You can polish your story or you like, but I can assure you if it's not anchored in structure pilot data, then the narrative is not gonna help you. The strongest commercial narrative doesn't come from brainstorming. It comes from proof. Your pilot tells you what actually resonated, what actually changed, where economic value showed up, what objections came up, who really influenced the decision. That's what sharpens narrative. So option D would be premature at this stage without doubling down on the case study because your narrative should be refined from evidence and it should not be instead of the evidence. So hopefully you're still all with me and. So hopefully you're still all with me and you agree with me and Mark that doubling down on the case study and gaining proof is the right option and the right priority in the next 90 days. So now let's just have a quick discussion about what does a fully scaled case study actually mean? It's not a testimonial, it's not a quote saying we really like it. What I'm talking about is baseline data. Post implementation data, measurable improvement, economic impact, clear workflow, story name, stakeholders, procurement, pathway, clarity, so that becomes commercial ammunition. That reduces your sales cycle, that's gonna strengthen your distributor negotiations. That's gonna change pricing conversations, and that's gonna make investor conversations easier. Once you've got that case study, you've got leverage. And when runway's tight, leverage matters more than anything else. And here's the real principle, with limited funds certainty. Beats activity. Spreading yourself across two pilots, distributor, onboarding, hiring, message refinement. Now doing all of those things may feel productive, but you'll end up with four half-built assets instead of one undeniably powerful asset. When you focus your attention and one undeniable case study can unlock distributors, it can unlock investors, it will unlock new hospitals, and it'll definitely help you unlock new export markets because you are not saying, we think this works anymore. You're saying, here's the data. That's a very, very different conversation. Now I'll add one nuance to what, I would do in this situation because while you're building that case study, I would actually probably still quietly pressure test the distributor, not fully activate, which is gonna take you loads of time. But just test them by asking a few questions. And you can do that by email. You don't have to even get on a call. Or you'd need to ask me. Okay, which accounts would you open first? Who are the decision makers? What objection that are you expecting? What economic argument will you lead with? If they can't answer those questions clearly, then they're not the right distributor, however enthusiastic they are, and you've saved yourself six months. So let me close on this regulatory approval is permission to begin a pilot study is curiosity. A keen distributor is potential, but only proof creates momentum. If you've got 90 days and limited runway, don't chase, reach, build leverage, turn one pilot into a commercial weapon, and then scale. Because the difference between a clever invention and an international MedTech business isn't technical strength. It's commercial proof, that's what's gonna protect your runway. Now, if you are listening to this thinking, actually, if I look at my business, we've got approval, we've got interest, but I'm not sure if you've got proof, then you're exactly where Lots of MedTech founders store, not because the product isn't good, but because the commercial structure isn't tight, and if you want me to pressure test your next 90 days and show you where you're commercially exposed across your business, book a healthcare Export accelerator discovery call using the link in the show notes. Thanks for listening. Keep listening and keep growing.